Therapy of Patients with T-cell Lymphomas and Leukemias Using an Anti-CD7 Monoclonal Antibody-Rich a Chain Immunotoxin

References

• Bertnesa V., Kirsch I., Hollis G., Johnson B., Bunn P. T-cell receptor gene rearrangements as clinical markers of human T-cell lymphomas. New England Journal of Medicine 1985; 313: 534–538
   PubMed Web of Science ®Google Scholar
• Harris N., Jaffe E., Stein H., Banks P., Chan J., Cleary M., Derol G., De Wolf-Peeters C., Falini B., Gatter K., et al. Perspective: A revised European-American classification of lymphoid neoplasms. Blood 1994; 84: 1361–1392
   PubMed Web of Science ®Google Scholar
• Longu D., DeVita V., Jaffe E., . Lymphocytic lymphomas. Cancer: Principles utid Practice of Oncology, V. DeVita, S. Hellman, S. Rosenberg, et al. J.B. Lippincott, Philadelphia 1993; 1859–1881
   Google Scholar
• Frankel A., Tagge E., Willingham M. Clinical trials of targeted toxins. Seminars in Cancer Biology 1995; 6: 307–317
   PubMed Web of Science ®Google Scholar
• LeMaistre C., Rosen S., Frankel A., Kornfeld S., Saria E., Meneghetti C., Drajesk J., Fishwild D., Scannon P., Byers V. Phase 1 trial of H65-RTA immunoconjugate in patients with cutaneous T-cell lymphoma. Blood 1991; 76: 1173–1182
   Google Scholar
• Waldman T., Pastan I., Gansow O., Junghans R. The multichain interleukin-2 receptor: a target for immunotherapy. Ann. Intern. Med. 1992; 116: 148–160
   PubMed Web of Science ®Google Scholar
• Kuzel T., Foss F., Hesketh P., Saleh M., Platanias L., Schwartz G., Craig F., Tolson K., Woodworth T. DAB389IL2 is well tolerated at doses inducing responses in IL-2 receptor expressing lymphomas. Blood 1993; 82(suppl. 1)137a
   Google Scholar
• Aruffo A., Seed B. Molecular cloning ol two CD7 (T-cell leukemia antigen) cDNAs by a COS cell expression system. EMRO Journal 1987; 11: 3313–3330
   Google Scholar
• Haynec B., Eiaenbarth G., Fauci A. Human lyniphocyte antigens: produclion of a monoclonal antibody that dcfines functional thymus-derived lymphocyte subsets. Proc. Natl. Acad. Sci. USA 1979; 76: 5829–5833
   PubMed Web of Science ®Google Scholar
• Lazarovits A., Osman N., Le Feuvre C., Ley S., Crumpton M. CD7 is associated with CD3 and CD45 on human T cells. Journal of Immunology 1994; 153: 3956–3966
   PubMed Web of Science ®Google Scholar
• Hertler A., Schlossman D., Borowitz M., Poplack D., Frankel A. A immunotoxin for the treatment of T-acute lymphoblastic leukemic meningitis studies in rhesus monkeys. Cancer Immunol. Immunother. 1989; 28: 59–66
   PubMed Web of Science ®Google Scholar
• Vallera D., Burns L., Frankel A., Sicheneder A., Kersey J. Laboratory preparation of a deglycosylated ricin toxin A chain containing imniunotoxin directed against a CD7 T lineage differentiation antigen for phase I human clinical studies involving T cell malignancies. J. Immunol. Merhods 1996; 197: 69–83
   PubMed Web of Science ®Google Scholar
• Janaen B., Vallera D., Jascz W., Nguyen D., Kersey J. Successful treatment of human acute T-cell leukemia in SCID mice using anti-CD7-deglycosylated ricin A, DA7. Cancer Research 1992; 52: 1314–1321
   PubMed Web of Science ®Google Scholar
• Lichtman S., Ratain M., Van Echo D., Rosner G., Egorin M., Budman D., Vogelzang N., Norton L., Schilsky R. Phase I trial of granulocyte-macrophage colony-stimulating factor plus high-dose cyclophosphamide given every 2 weeks: a Cancer and Leukemia Group B study. JNCI 1993; 85: 1319–1326
   PubMed Web of Science ®Google Scholar
• Sausville E., Headlee D., Stetler-Stevenson M., Jaffe E., Solomon D., Figg W., Herdt J., Kopp W., Rager H., Steinberg S., Ghetie V., Schindler J., Uhr J., Wittes R., Vitetta E. Continuous infusion of the anti-CD22 immunotoxin IgG-RFB4-SMPT-dgA in patients with B-cell lymphoma: a phase I study. Blood 1995; 85: 3457–3465
   PubMed Web of Science ®Google Scholar
• Hertler A., Schlossman D., Borowitz M., Laurent G., Jansen F., Schmidt C., Frankel A. A phase I study of T101-ricin A chain immunotoxin in refractory chronic lymphocytic leukemia. Journal of Biological Response Modjfiers 1988; 7: 97–113
   PubMedGoogle Scholar
• Hertler A., Spitler L., Frankel A. Humoral immune response to a ricin A chain immuntoxin in patients with metastatic melanoma. Cancer Drug Delivery 1987; 4: 245–253
   PubMedGoogle Scholar
• Amlot P., Stone M., Cunningham D., Fay J., Newman J., Collins R., May R., McCarthy M., Richardson J., Ghetie V., Ramilo O., Thorpe P., Uhr J., Vitetta E. A phase I study of an anti-CD22-deglycosylated ricin A chain immunotoxin in the treatment of B-cell lymphomas re. to conventional therapy. Blood 1993; 82: 2624–2633
   PubMed Web of Science ®Google Scholar
• Grossbard M., Lambert J., Goldmacher V., Spector N., Kinsella J., Eliseo L., Coral F., Taylor J., Blattler W., Epstein C., Nadler L. AntikB4-blocked ricin: a phase I trial of 7-day continuous infusion in patients with B-cell neoplasms. Journal of Clinical Oncology 1993; 11: 726–737
   PubMed Web of Science ®Google Scholar
• Uckun F. Annotation: immunotoxins for the treatment of leukaemia. British Journal of Haematology 1093; 85: 435–438
   Google Scholar
• Pai L., Wittes R., Setser A., Willingham M., Pastan I. Treatment of advanced solid tumors with immunotoxin LMB-1: an antibody linked to Pseudomonas exotoxin. Nature Medicine 1906; 2: 350–353
   Web of Science ®Google Scholar
• Soler-Rodriguez A., Chetie M., Oppenheimer-Marks N., Uhr J., Vitetta E. Ricin A-chain and ricin A-chain immunotoxins rapidly damage human endothelial cells: implications for vascular leak syndrome. Exp. Cell Res. 1993; 206: 227–234
   PubMed Web of Science ®Google Scholar
• Hertler A., Schlossman D., Borowitz M., Blythman H., Casellas P., Frankel A. An antiLCD5 immunotoxin for chronic lymphocytic leukemia: enhancement of cytotoxicity with human serum albumin-monensin. Int. J. Cancer 1989; 43: 215–219
   PubMed Web of Science ®Google Scholar
• Blakey D., Watson G., Knowles P., Thorpe P. Effect of chemical deglycosylation of ricin A chain on the in vivo fate and cytotoxic activity of an immunotoxin composed of ricin A chain and anti-Thy 1.1 antibody. Cancer Research 1987; 47: 947–952
   PubMed Web of Science ®Google Scholar
• Pastan I., Pai L., Brinkmann U., FitzGerald D. Recombinant toxins: new therapeutic agents for cancer. Ann. N. Y. Acad. Sci. 1995; 758: 345–354
   PubMed Web of Science ®Google Scholar
• Baluna R., Ghetie V., Oppenheimer-Marks N., Vitctta E. The binding of ricin A-chain to fibronection: Implications for vascular leak syndrome in immunotoxin-treated patients. Int'l. J. Immunopharm. 1997, in press
   Google Scholar
• Falini B., Pasqualucci L., Flenghi L., Bolognesi A., Kadin M., Stein H., Martelli M., Stirpe F. Anti-CD30 immunotoxins: experimental and clinical studies. Proc. Fourth Intl. Symposium on Immunotoxins, Myrtle Beach, 1995; 160
   Google Scholar
• Spitler L., Del Rio M., Khentigan A., Wedel N., Brophy N., Miller L., Harkonen W., Rosendorf L., Lee H., Mischak R., Kawahata R., Stoudemire J., Fradkin L., Bautista E., Scannon P. Therapy of patients with malignant melanoma using a monoclonal anti-melanoma antibody-ricin A chain immunotoxin. Cancer Research 1987; 47: 1717–1723
   PubMed Web of Science ®Google Scholar
• Could B., Borowitz M., Groves E., Carter P., Anthony D., Weiner L., Frankel A. Phase I study of an anti-breast cancer immunotoxin by continuous infusion: report of a targeted toxic effect not predicted by animal studies. JNCI 1989; 81: 775–781
   PubMed Web of Science ®Google Scholar
• Baluna R., Sausville E., Stone M., Stetler-Stevenson M., Uhr J., Vitetta E. Decreases in levels of serum fibronectin predict the severity of vascular leak syndrome in patients treated with ricin A-chain-containing immunotoxins. Clin. Cancer Research. 1996, in press
   PubMed Web of Science ®Google Scholar